John joined Sofinnova BioEquities as an Analyst and was promoted to Senior Analyst in 2025. He focuses on public biotech investments in all therapeutic areas.
Prior to joining Sofinnova, John began his investing career as a biotech Analyst at Parkman Healthcare Partners covering all SMid cap therapeutic areas. Before public investing, John joined the Street at Leerink covering SMid cap oncology.
John earned a Ph.D. in Molecular Engineering from the University of Chicago and a B.S. in Biomedical Engineering from Boston University.